AstraZeneca liver cancer combination therapy reduces risk of progression or death by 30%
Results from AstraZeneca's Phase III Emerald-3 trial showed that the regimen of durvalumab combined ...
Novartis's Secukinumab Phase III Trial Shows Sustained Remission Rate Twice That of Placebo
Novartis has announced new data from the Phase III REPLENISH trial evaluating Cosentyx (secukinumab)...
UK's Elementis Completes Sale of Pharmaceutical Manufacturing Business for €34.3 Million
Elementis plc has announced the completion of the sale of its pharmaceutical manufacturing business ...
U.S. Study: GLP-1 Drug Users See 35% Lower Breast Cancer Diagnosis Rate
An observational study led by Elizabeth McDonald, a professor of radiology at the Perelman School of...
Johnson & Johnson Releases Nipocalimab Data for Sjögren's Syndrome, Response Rate Reaches 62.5% in High Autoantibody Subgroup
On June 3, Johnson & Johnson announced new exploratory biomarker analyses from the Phase 2 DAHLI...
Brazil's Medical Cannabis Imports Hit Record High in March 2026, Up 60.1%
In March 2026, Brazil's medical cannabis imports reached a record high, with 23,199 import authoriza...
Germany's FundaMental Pharma Appoints Chief Medical Officer
FundaMental Pharma GmbH announced the appointment of Dr. Hans Eriksson as Chief Medical Officer, whe...
Mikron Automation Switzerland Provides Scalable Assembly Solutions for Pharmaceutical and Medical Devices
Mikron Automation, part of the Mikron Group, offers advanced assembly solutions for pharmaceutical a...
US-based RayzeBio Plans $150 Million Investment in Radiopharmaceutical Facility
On June 1, RayzeBio, a subsidiary of Bristol Myers Squibb, announced plans to invest approximately $...
Zhejiang, China Launches 225Ac-PSMA Clinical Study for Prostate Cancer and Completes First Patient Dosing
The Department of Nuclear Medicine at Zhejiang Cancer Hospital recently initiated an international m...